# Persistence and maturation of IgG antibodies in the first seven months following infection with SARS-CoV-2 in a prospective nationwide study



<sup>1</sup>Centre for Immunology of Infectious Diseases and Vaccines

<sup>2</sup> Centre for Infectious Diseases, Epidemiology and Surveillance

<sup>3</sup> Centre for Infectious Disease Control

National Institute for Public Health and the Environment, 3720 BA Bilthoven, The Netherlands

# ABSTRACT

# Background

The longevity of immunity following infection with SARS-CoV-2 is a major concern globally. Several studies report on a relative short period of circulating specific serum antibodies. Here, we study the concentrations of IgM, IgA and IgG-specific SARS-CoV-2 antibodies in seroconverted participants up to 7 months following onset of symptoms.

### Methods


Longitudinal blood samples from seroconverted participants (N=353) in the prospective, nationwide Pienter-Corona study, were collected. Per seroconverted participant, two to three consecutive serum samples were analysed for IgG, IgA and IgM antibody levels to SARS-CoV-2 Spike S1 and strength of antibody binding (avidity) in relation to the time since onset of disease symptoms. Results

While SARS-CoV-2-specific IgA and IgM antibodies were detected following infection, these declined after the first month post onset of disease. In contrast, specific IgG was still detected in 92% of the participants after 6-7 months. The half-life of IgG antibodies was 163 days and concentrations remained higher in symptomatic persons. Moreover, the avidity of IgG antibodies doubled over time.

### Conclusions

SARS-CoV-2-specific IgA and IgM antibodies wane within a few months whereas IgG persisted and showed increasing avidity over time, indicative of higher functionality and an underlying maturation of cellular immunity. These data help explain the previous different estimates of the duration of SARS-CoV-2-specific antibodies in various studies and point towards the presence of a memory against SARS-CoV-2.

Trial registration number: NL8473



The seroprevalence for SARS-CoV-2 antibodies in relation to time since onset of symptoms. A) The proportion of individuals with IgM, IgA and IgG antibodies. B) The proportion of persons with IgM antibodies depending on having symptoms (Systemic) or not (None or local). C and D) data as in B for IgA (C) and IgG (D). Data show that symptomatic persons more frequently have antibodies to SARS-CoV-2, also half a year after contraction of the virus. And that almost all persons still have IgG antibodies after more than half a year since onset of symptoms.